

Oxidative Coupling of (–)-Sclareol and Related Diols Leading to Oxepane Terpenoids


Hanane Bouanou,[†] Juan A. Gil,[†] Ramón Alvarez-Manzaneda,[‡] Rachid Chahboun,^{*,†} and Enrique Alvarez-Manzaneda^{*,†}

[†]Departamento de Química Orgánica, Facultad de Ciencias, Universidad de Granada, 18071 Granada, Spain

[‡]Área de Química Orgánica, Departamento de Química y Física, Universidad de Almería, 04120 Almería, Spain

Supporting Information

ABSTRACT: Treatment of (–)-sclareol and related compounds with lead tetraacetate affords tetracyclic compounds bearing a 2,8-dioxabicyclo[5.2.0]nonane moiety with complete regio- and stereoselectivity. This process, which is also applicable to 1,5-diols with a similar substitution pattern, facilitates the development of efficient syntheses toward oxepane terpenoids, such as aplysiastatin derivatives.




Natural products are frequently utilized as the starting material for synthesizing valuable compounds, providing various advantages in this respect. These processes make use of the stereochemistry and other structural features of the natural precursor, which makes it feasible to achieve the target compound in an efficient and economical way. One such natural compound is (–)-sclareol (**1**).¹ This labdane diterpene, which is the main component of the aerial parts of the clary sage *Salvia sclarea*, satisfies all the requisites for this purpose. Compound **1**, which has a *trans*-decalinic system with five stereogenic centers, is an inexpensive, commercially available compound. The use of this diterpene as a starting material usually involves the degradative oxidation of the carbon side chain and the suitable transformation of the C-8 hydroxyl group. The oxidant systems most often utilized for this purpose are $\text{RuCl}_3/3\text{H}_2\text{O}/\text{NaIO}_4$ ² or $\text{OsO}_4/\text{NaIO}_4$,^{3,5} or the more classic reagent KMnO_4 .⁴

Continuing our research into the oxidation of (–)-sclareol (**1**), we were interested in exploring processes involving radical species, which have received very little research attention. Indeed, only two articles in this respect have been published. Decorzant et al. reported the preparation of the odorant (–)-ambrox from diterpene **1**. Treatment with hydrogen peroxide in an acid medium produced a mixture of hydroperoxides and manoyl oxides; the degradation of 13-hydroperoxide epimers with Fe(II) and Cu(II) salts, via an alkoxy radical, afforded the target compound in 52% global yield.⁵ In addition, our group described a very efficient synthesis of manoyl oxide⁶ after treatment of diterpene **1** with cerium ammonium nitrate; the participation of oxygen radicals was postulated for the cyclization process.⁷ In general, chemical processes involving alkoxy radicals have been little studied, probably due to their high reactivity, particularly in the case of those derived from primary and secondary alcohols, and to the ready oxidation of this type of alcohols. Mihailovic reported the use of $\text{Pb}(\text{OAc})_4$ to convert different types of alcohols into variable mixtures of cyclic ethers and other oxidation products.⁸

The treatment of (–)-sclareol (**1**) with $\text{Pb}(\text{OAc})_4$ (1.5 equiv) in dichloromethane at room temperature for 12 h gave the tetracyclic diether **2** in high yield (Scheme 1). When the reaction was performed in benzene, a mixture of compounds resulted. When $\text{PhI}(\text{OAc})_2$ was utilized as the oxidant, the starting material remained unaltered.

Scheme 1. Reaction of (–)-Sclareol (**1**) with $\text{Pb}(\text{OAc})_4$



This unexpected result prompted us to explore the use of this reaction for the efficient preparation of terpenes bearing an oxepane moiety.⁹ Some interesting examples of this type of compound are found in nature, including sesquiterpenes, such as the cytotoxic (–)-aplysiastatin (**3**),¹⁰ (+)-palisadin B (**4**),¹¹ the bromoditerpene **5** and the related oxocane **6**,¹² the sesterterpene (+)-luffalactone (**7**),¹³ or the meros sesquiterpene bis(sulfate)–cyclophosphonodictyol A (**8**).¹⁴ (Figure 1).

In order to establish the scope of this oxidation, other diols with a substitution pattern similar to that of (–)-sclareol (**1**) were assayed (Table 1).

As can be seen, diols **1**, **9**, **11**, **13**, and **16** gave the corresponding diethers **2**, **10**, **12**, **14**, **15**, and **17**, having a 2,8-dioxabicyclo[5.2.0]nonane moiety, with complete regio- and stereoselectivity. This process could involve the Pb(IV) approach to the carbon–carbon double bond, probably assisted by the allyl hydroxyl group,¹⁶ to produce a complex that undergoes the attack of the C₈-hydroxyl group leading to

Received: July 28, 2016

Published: September 30, 2016




Figure 1. Some natural oxepane terpenes and related compounds.

intermediate **II**, which after C–O reductive elimination will give the bicyclic ether **2** (Scheme 2). At this point, we cannot rule out the intermediacy of radical or cationic species.¹⁷ On the other hand, intermediates are not detected in the course of the reaction, and a concerted process should not be excluded. It is important to note that diol **18**, the epimer of compound **16**, remains unaltered under the reaction conditions; in this case, the tricyclic intermediate similar to **II** cannot be formed, due to the 1,3-diaxial interaction between methyl groups. In the case of acyclic diol **19**, the 2,8-dioxabicyclo[5.2.0]nonane fragment is not present in the final compound, probably due to the flexibility of the monocyclic oxepane, which is unfavorable to the formation of the oxetane ring.

After obtaining the tetracyclic diether **2**, we studied the oxetane ring opening in order to prepare synthetic intermediates of oxepane terpenoids related to compounds **3**–**8**. We then examined the nucleophilic oxetane ring opening of compounds **2** and **17**. The most significant results obtained are shown in Table 2.

As can be seen, even though the treatment of diether **2** with LiBr gave alcohol **23** in low yield (entry 4), this compound was obtained in high yield when the oxetane ring opening was realized with TMSOTf (entry 7).

Compounds **21**–**25** appear to be suitable intermediates to prepare oxepane terpenoids related to the above natural products. Thus, the chloro derivative **22** was transformed into chloro alcohol **27a**, the corresponding 3-debromo derivative of natural oxepane **5** (Scheme 3).

The homoallyl alcohol moiety presented by compounds **21** and **23**–**25** can also be easily converted into the γ -butyrolactone fragment of aplysiastatins and related compounds. Thus, oxepane **24** was efficiently transformed into lactone **31**, a tetracyclic analogue of 3-debromoaplysiastatin (Scheme 4).

Following the same synthetic sequence, compound **25** could be readily converted into the corresponding tricyclic lactone (3-debromoaplysiastatin).

In summary, (–)-sclareol (**1**) and related 1,5-diols with a similar substitution pattern undergo an oxidative coupling process after treatment with lead tetraacetate, affording diethers bearing a 2,8-dioxabicyclo[5.2.0]nonane moiety. The oxetane ring opening of these compounds provides suitable intermediates for synthesizing oxepane terpenoids, such as aplysiastatin derivatives.

Table 1. Treatment of (–)-Sclareol (**1**) and Related Diols with Pb(OAc)₄


Entry	Diol ¹⁵	t	Product ^a
1		12h	
2		12h	
3		12h	
4		18h	
			(73% global)
5		12h	
6		24h	No reaction
7		14h	

^aThe relative stereochemistry of the resulting compounds was established on the basis of NOE experiments.

EXPERIMENTAL SECTION

General Methods. Unless stated otherwise, reactions were performed in oven-dried glassware under an argon atmosphere using dry solvents. Solvents were dried as follows: THF and MeOtBu over Na–benzophenone, benzene over Na, and DCM and MeOH over CaH₂. DMF was dried over 4 Å molecular sieves. Thin-layer chromatography was performed using F254 precoated plates (0.25

Scheme 2. Possible Transformation of (–)-Sclareol (1) into Tetracyclic Ether 2 via Intermediate II




mm) and visualized by UV fluorescence quenching and phosphomolybdic acid solution staining. Flash chromatography was performed on silica gel (230–400 mesh). Chromatography separations were carried out by conventional column on silica gel 60 (230–400 mesh) using hexanes–MeOTBu (H–E) mixtures of increasing polarity. ^1H and ^{13}C NMR spectra were recorded at 500 and 125 MHz, respectively. CDCl_3 was treated with K_2CO_3 . Chemical shifts (δ H) are reported in parts per million (ppm) referenced to the appropriate residual solvent peak and tetramethylsilane. Data for ^1H NMR spectra are reported as follows: chemical shift (δ ppm) (multiplicity, coupling constant (Hz), integration) with the abbreviations s, br s, d, br d, t, q, and m denoting singlet, broad singlet, doublet, broad doublet, triplet, quartet, and multiplet, respectively. J = coupling constant (Hz). Data for ^{13}C NMR spectra are reported in terms of chemical shift relative to Me_4Si (δ 0.0), and the signals were assigned utilizing DEPT experiments and on the basis of heteronuclear correlations. Infrared spectra were recorded as thin films or as solids on a FTIR spectrophotometer with samples between sodium chloride plates or as potassium bromide pellets and are reported in frequency of absorption (cm^{-1}). Only selected absorbances (ν_{max}) are reported. ($[\alpha]_{\text{D}}$) measurements were carried out in a polarimeter with a 1 dm length cell and using CHCl_3 as solvent. Concentration is expressed in mg/mL. HRMS were recorded on a spectrometer, utilizing a quadrupole MS/MS analyzer and using FAB with thioglycerol or glycerol matrix doped in NaI 1%.

General Procedure for the Reaction of Diols with $\text{Pb}(\text{OAc})_4$. Lead tetraacetate (2 mmol) was added to a solution of diol (2 mmol) in dichloromethane (10 mL), the resulting mixture was stirred at room temperature for the specified time, and the course of the reaction was monitored by TLC. When the starting material was consumed, the mixture was filtered on a silica gel pad, and the solvent was evaporated. The crude residue was dissolved in ether (10 mL), and the organic solution was successively washed with 5% aq NaHSO_3 (3×10 mL), H_2O (4×10 mL), and brine (10 mL). The organic phase was dried over anhyd Na_2SO_4 and evaporated to give the bicyclic ether.

(4*aS*,6*aR*,7*aR*,9*aS*,11*aR*,11*bS*)-4,4,6*a*,9*a*,11*b*-Pentamethyltetradecahydro-1*H*-naphtho[2,1-*b*]oxeto[2,3-*f*]oxepine (2). Colorless oil, 963 mg, 97%. $[\alpha]_{\text{D}}^{25} +6.4$ (c 1.1, CHCl_3). ^1H NMR (CDCl_3 , 500 MHz) δ : 0.78 (s, 3H), 0.81 (s, 3H), 0.86 (s, 3H), 1.10 (ddd, J = 16.8, 13.3, 4.2 Hz, 1H), 1.27 (s, 3H), 1.40 (s, 3H), 1.33–1.69 (m, 14H), 2.51 (ddd, J = 17.4, 17.1, 6.6 Hz, 1H), 4.16 (dd, J = 5.8, 3.4 Hz, 1H), 4.19 (dd, J = 7.2, 3.4 Hz, 1H), 4.68 (dd, J = 7.2, 5.8 Hz, 1H). ^{13}C NMR (CDCl_3 , 125 MHz) δ : 15.4 (CH_3), 18.7 (CH_2), 18.7 (CH_2), 20.2 (CH_2), 21.5 (CH_3), 22.6 (CH_2), 23.7 (CH_3), 31.7 (CH_2), 33.3 (C), 33.4 (CH_3), 38.4 (C), 38.7 (CH_2), 40.3 (CH_2), 41.7 (CH_2), 52.4 (CH), 56.4 (CH), 71.5 (CH), 72.0 (CH_2), 79.5 (C), 90.4 (C). IR (film): 1594, 1457, 1386, 1214, 1160, 1103, 1084, 973, 926, 875, 772, 665 cm^{-1} . HRMS (FAB) m/z : calcd for $\text{C}_{20}\text{H}_{34}\text{O}_2\text{Na}$ ($M + \text{Na}^+$) 329.2457, found 329.2463.

(4*aS*,4*aR*,6*aR*,7*aR*,9*aR*,11*aR*,11*bS*)-4,6*a*,9*a*,11*b*-Tetramethyltetradecahydro-1*H*-naphtho[2,1-*b*]oxeto[2,3-*f*]oxepin-4-yl)methanol (10). Colorless oil, 198 mg, 95%. $[\alpha]_{\text{D}}^{25} +7.06$ (c 0.11, CHCl_3). ^1H NMR (CDCl_3 , 500 MHz) δ : 0.82 (s, 3H), 0.99 (s, 3H), 1.27 (s, 3H),

Table 2. Nucleophilic Oxetane Ring Opening for Compounds 2 and 17




Entry	Conditions	t	Product
1	2, CH_3COCl , N,N -dimethylaniline, CH_2Cl_2 , rt	72h	 21 (80%)
2	2, POCl_3 , pyridine, 0 °C	15h	 22 (56%)
3	2, SOCl_2 , NEt_3 , -30 °C	3 h	Complex mixture
4	2, LiBr, DMF, 70 °C	72h	 23 (30%)
5	2, $\text{CH}_2=\text{CHMgBr}$, THF, reflux	72h	Starting material
6	2, MgBr_2 , toluene, reflux	15h	Complex mixture
7	2, TMSOTf, Et_2NPr^t , CH_2Cl_2 , 0 °C,	5min	 23 (97%)
8	2, TBSOTf, Et_2NPr^t , CH_2Cl_2 , 0 °C,	5min	 24 (99%)
9	17, TBSOTf, Et_2NPr^t , CH_2Cl_2 , 0 °C,	15min	 25 (97%)


1.43 (s, 3H), 0.88–1.81 (m, 15H), 2.54 (td, J = 11.9, 11.4, 7.5 Hz, 2H), 3.44 (d, J = 10.9 Hz, 1H), 3.69 (d, J = 10.9 Hz, 1H), 4.18 (dd, J = 5.9, 3.4 Hz, 1H), 4.22 (dd, J = 7.3, 3.4 Hz, 1H), 4.70 (dd, J = 7.3, 5.9 Hz, 1H). ^{13}C NMR (CDCl_3 , 125 MHz) δ : 15.9 (CH_3), 18.4 (CH_2), 18.9 (CH_2), 20.4 (CH_2), 22.7 (CH_3), 23.6 (CH_3), 27.0 (CH_3), 31.7 (CH_2), 35.4 (CH_2), 38.4 (C), 38.6 (C), 39.1 (CH_2), 40.4 (CH_2), 52.5 (CH), 57.0 (CH), 65.3 (CH_2), 71.5 (CH), 72.1 (CH_2), 79.3 (C), 90.2 (C). IR (film): 2959, 1426, 1255, 1125, 1075, 960, 754, 613 cm^{-1} . HRMS (FAB) m/z : calcd for $\text{C}_{20}\text{H}_{34}\text{O}_3\text{Na}$ ($M + \text{Na}^+$) 345.2406, found 345.2398.

(4*aS*,5*aS*,6*aR*,7*aR*,9*aR*,11*aR*,11*bS*)-4,4,6*a*,9*a*,11*b*-Pentamethyltetradecahydro-1*H*-naphtho[2,1-*b*]oxeto[2,3-*f*]oxepin-5-yl Acetate (12). Colorless oil, 228 mg, 92%. $[\alpha]_{\text{D}}^{25} +21.8$ (c 0.6, CHCl_3). ^1H

Scheme 3. Synthesis of Chloro Alcohols 27a,b from Oxepane 22



Scheme 4. Synthesis of Lactone 31 from Oxepane 24



NMR (CDCl₃, 500 MHz) δ : 0.83 (s, 3H), 0.84 (s, 3H), 1.03 (s, 3H), 1.23 (s, 3H), 1.40 (s, 3H), 0.88–2.21 (m, 14H), 2.02 (s, 3H), 4.25 (t, J = 5.9 Hz, 1H), 4.33 (dd, J = 5.9, 5.3 Hz, 1H), 4.52 (dd, J = 7.3, 5.3 Hz, 1H), 5.04 (dd, J = 7.3, 5.9 Hz, 1H). ¹³C NMR (CDCl₃, 125 MHz) δ : 17.4 (CH₃), 18.6 (CH₂), 19.7 (CH₂), 20.6 (CH₃), 22.0 (CH₃), 22.3 (CH₃), 24.7 (CH₃), 33.5 (C), 36.1 (CH₃), 38.6 (CH₂), 39.2 (C), 40.1 (CH₂), 43.1 (CH₂), 49.5 (CH₂), 58.1 (CH), 64.0 (CH), 70.9 (CH₂), 70.9 (CH), 72.8 (CH), 79.2 (C), 91.4 (C), 170.3 (C). IR (film): 1736, 1458, 1367, 1245, 1166, 1106, 1029, 975 cm⁻¹. HRMS (FAB) m/z : calcd for C₂₂H₃₆O₄Na (M + Na⁺) 387.2511, found 387.2526.

(4*aS*,6*aR*,7*aS*,9*aS*,11*aR*,11*bS*)-4,4,6*a*,7*a*,9*a*,11*b*-Hexamethyltetradecahydro-1*H*-naphtho[2,1-*b*]oxeto[2,3-*f*]oxepine (14). Colorless oil, 73 mg, 32%. [α]_D²⁵ +7.4 (c 0.1, CHCl₃). ¹H NMR (CDCl₃, 500 MHz) δ : 0.77 (s, 6H), 0.85 (s, 3H), 1.13 (s, 3H), 1.31 (s, 3H), 1.33 (s, 3H), 0.76–1.68 (m, 15H), 2.37 (m, 1H), 3.59 (d, J = 13.0 Hz, 1H), 3.73 (d, J = 13.0 Hz, 1H). ¹³C NMR (CDCl₃, 125 MHz) δ : 15.6 (CH₃), 18.6 (CH₂), 19.2 (CH₃), 19.5 (CH₂), 20.6 (CH₂), 21.3 (CH₃), 23.5 (CH₃), 33.3 (C), 37.9 (CH₂), 39.0 (CH₂), 39.2 (C), 39.9 (CH₂), 42.0 (CH₂), 49.4 (CH₃), 56.3 (CH), 58.0 (CH), 64.2 (C), 65.5 (CH₂), 65.9 (C), 72.8 (C), 79.4 (C). IR (film): 1594, 1458, 1385, 1261, 1082, 801 cm⁻¹. HRMS (FAB) m/z : calcd for C₂₁H₃₆O₂Na (M + Na⁺) 343.2613, found 343.2622.

(4*aS*,6*aR*,7*aR*,9*aS*,11*aR*,11*bS*)-4,4,6*a*,7*a*,9*a*,11*b*-Hexamethyltetradecahydro-1*H*-naphtho[2,1-*b*]oxeto[2,3-*f*]oxepine (15). Colorless oil, 94 mg, 41%. [α]_D²⁵ +5.4 (c 0.16, CHCl₃). ¹H NMR (CDCl₃, 500 MHz) δ : 0.77 (s, 3H), 0.78 (s, 3H), 0.87 (s, 3H), 1.18 (s, 3H), 1.36 (s, 3H), 1.55 (s, 3H), 0.75–1.80 (m, 14H), 2.16 (m, 1H), 2.34 (m, 1H), 3.89 (d, J = 5.0 Hz, 1H), 4.40 (d, J = 5.0 Hz, 1H). ¹³C

NMR (CDCl₃, 125 MHz) δ : 16.0 (CH₃), 18.8 (CH₂), 19.6 (CH₂), 20.0 (CH₂), 21.9 (CH₃), 22.8 (CH₃), 25.2 (CH₃), 33.4 (CH₃), 38.4 (C), 39.2 (CH₂), 40.1 (CH₂), 41.8 (CH₂), 44.4 (CH₂), 49.4 (CH), 55.9 (CH), 64.7 (CH), 72.8 (C), 76.9 (C), 81.0 (C), 81.3 (CH₂), 92.5 (C). IR (film): 1706, 1460, 1379, 1194, 1086, 973 cm⁻¹. HRMS (FAB) m/z : calcd for C₂₁H₃₆O₂Na (M + Na⁺) 343.2613, found 343.2622.

(2*aS*,3*aS*,7*aS*)-3*a*,7,7,9*a*-Tetramethyldecahydro-2*H*-benzo[*b*]oxeto[2,3-*f*]oxepine (17). Colorless oil, 249 mg, 93%. [α]_D²⁵ -53.9 (c 0.12, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ : 0.83 (s, 3H), 0.92 (s, 3H), 1.29 (s, 3H), 1.41 (s, 3H), 1.20–1.65 (m, 11H), 4.18–4.24 (m, 2H), 4.70 (dd, J = 7.1, 5.8 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ : 19.8 (CH₂), 20.3 (CH₂), 20.9 (CH₃), 22.7 (2 x CH₃), 32.0 (CH₂), 33.2 (CH₃), 35.0 (C), 37.9 (CH₂), 41.9 (CH₂), 48.3 (CH), 71.7 (CH), 72.1 (CH₂), 79.5 (C), 90.4 (C). IR (film): 1463, 1426, 1380, 1274, 1123, 1073, 1039, 959 cm⁻¹. HRMS (FAB) m/z : calcd for C₁₅H₂₆O₂Na (M + Na⁺) 261.1830, found 261.1842.

((2*R*,3*S*)-3-Hydroxy-3,7,7-trimethyloxepan-2-yl)methyl Acetate (20). Colorless oil, 267 mg, 50%. [α]_D²⁵ -3.5 (c 0.13, CHCl₃). ¹H NMR (CDCl₃, 500 MHz) δ : 1.14 (s, 3H), 1.17 (s, 3H), 1.20 (s, 3H), 1.21–1.74 (m, 7H), 2.05 (s, 3H), 3.60 (dd, J = 9.0, 3.5 Hz, 1H), 3.97 (dd, J = 11.3, 9.0 Hz, 1H), 4.31 (dd, J = 11.3, 3.5 Hz, 1H). ¹³C NMR (CDCl₃, 125 MHz) δ : 18.4 (CH₂), 21.2 (CH₃), 24.7 (CH₃), 27.2 (CH₃), 28.4 (CH₃), 40.4 (CH₂), 45.6 (CH₂), 63.9 (CH₂), 72.1 (C), 73.4 (CH), 75.8 (C), 171.2 (C). IR (film): 2968, 2928, 1739, 1599, 1463, 1368, 1123 cm⁻¹. HRMS (FAB) m/z : calcd for C₁₂H₂₂O₄Na (M + Na⁺) 253.1416, found 253.1404.

((4*S*,5*aR*,7*aS*,11*aS*,11*bR*)-5*a*,8,8,11*a*-Tetramethyl-3-methylenetetradecahydronaphtho[2,1-*b*]oxepin-4-yl)methyl Acetate (21). *N,N*-Dimethylaniline (4 mL, 32 mmol) and CH₃COCl (1.15 mL, 16.3 mmol) were added to a solution of 2 (1 g, 3.26 mmol) in anhydrous CH₂Cl₂ (30 mL), and the mixture was allowed to stir at room temperature under argon atmosphere for 72 h. Then the reaction was quenched with water (10 mL), and ether was added (30 mL). The organic solution was washed with 10% HCl (6 x 15 mL) and brine (2 x 15 mL), dried over anhydrous Na₂SO₄ and evaporated to yield 21 (900 mg, 80%). [α]_D²⁵ +27.8 (c 0.11, CHCl₃). ¹H NMR (CDCl₃, 500 MHz) δ : 0.78 (s, 3H), 0.82 (s, 3H), 0.86 (s, 3H), 1.18 (s, 3H), 1.18–1.61 (m, 14H), 2.05 (s, 3H), 1.88–1.97 (m, 1H), 2.63 (m, 1H), 3.91 (dd, J = 11.3, 8.5 Hz, 1H), 4.13 (dd, J = 11.3, 3.4 Hz, 1H), 4.43 (brs, 1H), 4.74 (s, 1H), 4.87 (s, 1H). ¹³C NMR (CDCl₃, 400 MHz) δ : 16.2 (CH₃), 18.9 (CH₂), 20.5 (CH₃), 21.2 (CH), 21.6 (CH₃), 22.8 (CH₂), 23.7 (CH₃), 31.0 (CH₂), 33.5 (C), 33.6 (CH₃), 38.3 (C), 38.6 (CH₂), 40.5 (CH₂), 42.1 (CH₂), 53.4 (CH), 56.3 (CH), 68.0 (CH₃), 70.1 (CH), 79.1 (C), 107.9 (CH₂), 150.8 (C), 171.2 (C). IR (film): 1743, 1457, 1381, 1232, 1105, 1040 cm⁻¹. HRMS (FAB) m/z : calcd for C₂₂H₃₆O₃Na (M + Na⁺) 371.2562, found 371.2555.

(4*S*,5*aR*,7*aS*,11*aS*,11*bR*)-4-(Chloromethyl)-5*a*,8,8,11*a*-tetramethyl-3-methylenetetradecahydronaphtho[2,1-*b*]oxepine (22). Pyridine (1 mL) and POCl₃ (0.5 mL) were added to a solution of 2 (100 mg, 0.326 mmol) previously cooled at 0 °C, and the mixture was allowed to stir under argon atmosphere for 15 h. Then the reaction was carefully quenched at 0 °C with water (1 mL), and ether was added (25 mL). The organic solution was washed with 10% HCl (3 x 10 mL) and brine (3 x 10 mL), dried over anhydrous Na₂SO₄ and evaporated to afford a crude product that was purified by flash chromatography on silica gel (30% ether/hexane) to yield 22 (40 mg, 56%). [α]_D²⁵ +68.9 (c 0.1, CHCl₃). ¹H NMR (CDCl₃, 500 MHz) δ : 0.78 (s, 3H), 0.82 (s, 3H), 0.86 (s, 3H), 1.23 (s, 3H), 1.25–1.69 (m, 14H), 2.03 (dd, J = 11.9, 8.3 Hz, 1H), 2.62 (q, J = 10.1, 1H), 3.41 (dd, J = 11.2, 8.9 Hz, 1H), 3.53 (dd, J = 11.2, 3.1 Hz, 1H), 4.37 (d, J = 8.2 Hz, 1H), 4.73 (s, 1H), 4.91 (s, 1H). ¹³C NMR (CDCl₃, 125 MHz) δ : 16.2 (CH₃), 18.9 (CH₂), 20.4 (CH₂), 21.6 (CH₃), 22.8 (CH₂), 23.7 (CH₃), 31.0 (CH₂), 33.4 (C), 33.6 (CH₃), 38.3 (C), 38.5 (CH₂), 40.5 (CH₂), 42.0 (CH₂), 49.1 (CH₂), 53.4 (CH), 56.4 (CH), 72.5 (CH), 79.3 (C), 108.5 (CH₂), 151.8 (C). IR (film): 1637, 1457, 1383, 1130, 1100, 1038, 946, 894, 746, 664 cm⁻¹. HRMS (FAB) m/z : calcd for C₂₀H₃₃ClONa (M + Na⁺) 347.2118, found 347.2131.

((4*S*,5*aR*,7*aS*,11*aS*,11*bR*)-5*a*,8,8,11*a*-Tetramethyl-3-methylenetetradecahydronaphtho[2,1-*b*]oxepin-4-yl)methanol (**23**). LiBr (903 mg, 10.4 mmol) was added to a solution of **2** (80 mg, 2.6 mmol) in anhydrous DMF (10 mL), and the mixture was allowed to stir at 70 °C under argon atmosphere for 72 h. Then the reaction was quenched with water (1 mL), and ether was added (30 mL). The organic solution was washed with water (4 × 25 mL) and brine (3 × 20 mL), dried over anhyd Na₂SO₄, and evaporated to afford a crude product that was purified by flash chromatography on silica gel (30% ether/hexane) to yield **23** (50 mg, 30%). Colorless oil. [α]_D²⁵ +70.9 (c 0.6, CHCl₃). ¹H NMR (CDCl₃, 500 MHz) δ : 0.79 (s, 3H), 0.81 (s, 3H), 0.86 (s, 3H), 1.06 (ddd, *J* = 13.4, 13.4, 4.1 Hz, 1H), 1.22 (s, 3H), 1.19–1.70 (m, 14H), 2.03 (ddd, *J* = 10.7, 8.3, 1.5 Hz, 1H), 2.11 (brs, 1H), 2.57 (m, 1H), 3.37 (dd, *J* = 11.0, 9.0 Hz, 1H), 3.49 (dd, *J* = 11.0, 4.0 Hz, 1H), 4.31 (m, 1H), 4.65 (s, 1H), 4.82 (s, 1H). ¹³C NMR (CDCl₃, 125 MHz) δ : 16.2 (CH₂), 18.9 (CH₂), 20.5 (CH₂), 21.6 (CH₃), 22.8 (CH₂), 23.9 (CH₃), 30.8 (CH₂), 33.5 (C), 33.6 (CH₃), 38.4 (C), 39.1 (CH₂), 40.5 (CH₂), 42.0 (CH₂), 53.5 (CH), 56.4 (CH), 66.2 (CH₂), 72.8 (CH), 79.3 (C), 107.0 (CH₂), 151.0 (C). IR (film): 3461, 1643, 1454, 1412, 1095, 1041, 888, 756 cm⁻¹. HRMS (FAB) *m/z*: calcd for C₂₀H₃₄O₂Na (M + Na⁺) 329.2457, found 329.2442.

Treatment of Compound 2 with TMSOTf. Obtention of Alcohol 23. *N,N*-Diisopropylethylamine (0.26 mL, 1.47 mmol) and TMSOTf (0.21 mL, 1.17 mmol) were added to a solution of **2** (300 mg, 0.98 mmol) in anhydrous CH₂Cl₂ (15 mL), and the mixture was allowed to stir at 0 °C under argon atmosphere for 5 min. Then the reaction was carefully quenched with water (0.5 mL), and ether (20 mL) was added. The organic solution was washed with water (3 × 10 mL) and brine (2 × 10 mL), dried over anhyd Na₂SO₄, and evaporated to afford a crude product that was purified by flash chromatography on silica gel (5% ethyl acetate/hexane) to yield alcohol **23** (359 mg, 97%) as colorless oil.

tert-Butyldimethyl(((4*S*,5*aR*,7*aS*,11*aS*,11*bR*)-5*a*,8,8,11*a*-tetramethyl-3-methylenetetradecahydronaphtho[2,1-*b*]oxepin-4-yl)-methoxy)silane (**24**). *N,N*-Diisopropylethylamine (1.7 mL, 9.8 mmol) and TBSOTf (0.9 mL, 4.9 mmol) were added to a solution of **2** (1 g, 4.9 mmol) in anhydrous CH₂Cl₂ (30 mL), and the mixture was allowed to stir at 0 °C under argon atmosphere for 5 min. Then the reaction was carefully quenched with water (2 mL), and ether (30 mL) was added. The organic solution was washed with water (3 × 10 mL) and brine (2 × 10 mL), dried over anhyd Na₂SO₄, and evaporated to afford a crude product that was purified by flash chromatography on silica gel (5% ethyl acetate/hexane) to yield **24** (1.36 g, 99%) as colorless oil. [α]_D²⁵ +45.9 (c 0.13, CHCl₃). ¹H NMR (CDCl₃, 500 MHz) δ : 0.06 (s, 6H), 0.78 (s, 3H), 0.82 (s, 3H), 0.86 (s, 3H), 0.89 (s, 9H), 1.12 (ddd, *J* = 13.5, 13.3, 4.0 Hz, 1H), 1.13 (s, 3H), 1.21–1.67 (m, 13H), 1.97 (ddd, *J* = 9.2, 5.7, 1.4 Hz, 1H), 2.58 (q, *J* = 10 Hz, 1H), 3.48 (dd, *J* = 10.5, 5.0 Hz, 1H), 3.52 (dd, *J* = 10.5, 6.3 Hz, 1H), 4.22 (t, *J* = 5.8 Hz, 1H), 4.69 (t, *J* = 1.36 Hz, 1H), 4.81 (d, *J* = 0.8 Hz, 1H). ¹³C NMR (CDCl₃, 125 MHz) δ : -5.1 (CH₃), -4.8 (CH₃), 16.3 (CH₃), 18.6 (CH₂), 19.0 (C), 20.6 (CH₂), 21.6 (CH₃), 22.9 (CH₂), 23.8 (CH₃), 26.1 (3 CH₃), 31.0 (CH₂), 33.5 (CH₃), 33.6 (C), 38.3 (CH₂), 38.7 (C), 40.5 (CH₂), 42.1 (CH₂), 53.4 (CH), 56.4 (CH), 67.9 (CH₂), 73.3 (CH), 78.7 (C), 107.1 (CH₂), 151.9 (C). IR (film): 1461, 1381, 1252, 1122, 1085, 836, 775 cm⁻¹. HRMS (FAB) *m/z*: calcd for C₂₆H₄₈O₂SiNa (M + Na⁺) 443.3321, found 443.3312.

tert-Butyldimethyl(((2*R*,5*aS*,9*aS*)-6,6,9*a*-trimethyl-3-methylenedecahydrobenzo[*b*]oxepin-2-yl)methoxy)silane (**25**). *N,N*-Diisopropylethylamine (0.22 mL, 1.26 mmol) and TBSOTf (0.36 mL, 1.57 mmol) were added to a solution of **11** (250 mg, 1.05 mmol) in anhydrous CH₂Cl₂ (15 mL) cooled at 0 °C, and the mixture was allowed to stir at this temperature under argon atmosphere for 15 min. Then the reaction was carefully quenched with water (1 mL), and ether (20 mL) was added. The organic solution was washed with water (3 × 10 mL) and brine (2 × 10 mL), dried over anhyd Na₂SO₄, and evaporated to afford a crude product that was purified by flash chromatography on silica gel (5% ethyl acetate/hexane) to yield **25** (359 mg, 97%) as a colorless syrup. [α]_D²⁵ -20.4 (c 0.12, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ : 0.05 (s, 3H), 0.07 (s, 3H), 0.82 (s, 3H),

0.88 (s, 3H), 0.89 (s, 9H), 1.20 (s, 3H), 1.59–1.40 (m, 9H), 2.60 (brdt, *J* = 15.2, 10.8 Hz, 2H), 3.56–3.45 (m, 2H), 4.22 (brdd, *J* = 6.2 Hz, 1H), 4.72 (d, *J* = 1.6 Hz, 1H), 4.81 (d, *J* = 1.6 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ : -5.0 (CH₃), -4.7 (CH₃), 18.6 (C), 20.8 (CH₂), 21.6 (CH₃), 22.8 (CH₃), 23.8 (CH₂), 26.1 (3 CH₃), 31.2 (CH₂), 33.6 (CH₃), 34.9 (C), 37.8 (CH₂), 42.0 (CH₂), 49.2 (CH), 67.9 (CH₂), 73.5 (CH), 78.6 (C), 107.3 (CH₂), 151.7 (C). IR (film): 1722, 1426, 1255, 1124, 1074, 960 cm⁻¹. HRMS (FAB) *m/z*: calcd for C₂₁H₄₀O₂SiNa (M + Na⁺) 375.2695, found 375.2709.

((4*S*,5*aR*,7*aS*,11*aS*,11*bR*)-4-(Chloromethyl)-5*a*,8,8,11*a*-tetramethyldecadecahydronaphtho[2,1-*b*]oxepin-3(2*H*)-one (**26**). An ozone stream was bubbled into a solution of **22** (80 mg, 0.246 mmol) in anhydrous CH₂Cl₂ previously cooled at -78 °C for 1 h. When the reaction finished, an argon stream was bubbled to eliminate excess ozone. Then PPh₃ was added to the cooled solution, and the mixture was allowed to stir for 2 h. Solvent was evaporated to afford a crude product that was purified by flash chromatography on silica gel (10% ether/hexane) to yield **26** (66 mg, 83%). [α]_D²⁵ +78.5 (c 0.11, CHCl₃). ¹H NMR (CDCl₃, 500 MHz) δ : 0.79 (s, 3H), 0.85 (s, 3H), 0.86 (s, 3H), 1.25 (s, 3H), 1.40–1.78 (m, 14H), 2.18 (ddd, *J* = 11.4, 10.9, 2.0 Hz, 1H), 3.22 (q, *J* = 10.3 Hz, 1H), 3.63 (dd, *J* = 11.2, 6.4 Hz, 1H), 3.67 (dd, *J* = 11.2, 2.8 Hz, 1H), 4.02 (dd, *J* = 6.2, 3.0 Hz, 1H). ¹³C NMR (CDCl₃, 125 MHz) δ : 15.6 (CH₃), 18.4 (CH₂), 18.8 (CH₂), 20.3 (CH₂), 21.5 (CH₃), 23.5 (CH₃), 33.4 (C), 33.5 (CH₃), 38.0 (CH₂), 38.5 (CH₂), 38.7 (C), 40.3 (CH₂), 41.8 (CH₂), 45.6 (CH₂), 53.7 (CH), 56.3 (CH), 76.4 (CH), 80.1 (C), 215.6 (C). IR (film): 1747, 1697, 1616, 1457, 1370, 1222, 1125, 1056, 1009, 930, 771, 665 cm⁻¹. HRMS (FAB) *m/z*: calcd for C₁₉H₃₁ClO₂Na (M + Na⁺) 349.1910, found 349.1902.

((3*R*,4*S*,5*aR*,7*aS*,11*aS*,11*bR*)-4-(Chloromethyl)-3,5*a*,8,8,11*a*-pentamethyltetradecahydronaphtho[2,1-*b*]oxepin-3-ol (**27a**) and (3*S*,4*S*,5*aR*,7*aS*,11*aS*,11*bR*)-4-(Chloromethyl)-3,5*a*,8,8,11*a*-pentamethyltetradecahydronaphtho[2,1-*b*]oxepin-3-ol (**27b**). A CH₃MgBr solution (0.18 mL, 1.4 M THF/toluene, 0.18 mmol) was added to a solution of **27** (120 mg, 0.36 mmol) in anhydrous THF (15 mL) previously cooled at -30 °C, and the mixture was allowed to stir under argon atmosphere for 1 h. Then 10% HCl (1 mL) was added, and the mixture was allowed to stir for 5 min more. The solvent was evaporated, and ether was added (30 mL). The organic solution was washed with water (3 × 10 mL) and brine (15 mL), dried over anhyd Na₂SO₄, and evaporated to afford a crude product that was purified by flash chromatography on silica gel (5% ether/hexane) to yield **27a** (49 mg, 38%) and **27b** (70 mg, 57%). Compound **27a**. [α]_D²⁵ +26.6 (c 0.1, CHCl₃). ¹H NMR (CDCl₃, 500 MHz) δ : 0.77 (s, 3H), 0.78 (s, 3H), 0.86 (s, 3H), 0.84–0.93 (m, 1H), 1.15 s, 3H), 1.18 (s, 3H), 1.23–1.84 (m, 15H), 3.21 (brs, 1H), 3.35 (dd, *J* = 11.0, 9.7 Hz, 1H), 3.80 (dd, *J* = 9.4, 1.8 Hz, 1H), 3.97 (dd, *J* = 11.0, 2.0 Hz, 1H). ¹³C NMR (CDCl₃, 125 MHz) δ : 16.2 (CH₃), 18.5 (CH₂), 19.1 (CH₂), 20.89 (CH₂), 21.1 (CH₃), 21.7 (CH₃), 24.1 (CH₃), 33.3 (C), 33.3 (CH₃), 39.0 (C), 39.3 (CH₂), 39.7 (C), 42.0 (CH₂), 45.6 (CH₂), 47.5 (CH₂), 56.3 (CH), 58.3 (CH), 75.3 (C), 76.0 (CH), 78.7 (C). HRMS (FAB) *m/z*: calcd for C₂₀H₃₅ClO₂Na (M + Na⁺) 365.2223, found 365.2236. Compound **27b**. [α]_D²⁵ +7.9 (c 0.13, CHCl₃). ¹H NMR (CDCl₃, 500 MHz) δ : 0.79 (s, 3H), 0.85 (s, 3H), 0.86 (s, 3H), 1.10 (ddd, *J* = 11.4, 10.9, 2.3 Hz, 1H), 1.25 (s, 3H), 1.36 (s, 3H), 1.40–1.78 (m, 14H), 2.18 (ddd, *J* = 11.4, 10.9, 2.0 Hz, 1H), 3.22 (q, *J* = 10.3 Hz, 1H), 3.63 (dd, *J* = 11.2, 6.4 Hz, 1H), 3.67 (dd, *J* = 11.2, 2.8 Hz, 1H), 4.02 (dd, *J* = 6.2, 3.0 Hz, 1H). ¹³C NMR (CDCl₃, 125 MHz) δ : 16.2 (CH₃), 18.1 (CH₂), 18.5 (CH₂), 20.9 (CH₂), 21.1 (CH₃), 24.1 (CH₃), 24.9 (CH₃), 33.3 (C), 33.30 (CH₃), 39.0 (C), 39.1 (CH₂), 39.6 (CH₂), 42.1 (CH₂), 44.8 (CH₂), 45.5 (CH₂), 56.3 (CH), 58.1 (CH), 72.7 (C), 74.4 (CH), 79.3 (C). HRMS (FAB) *m/z*: calcd for C₂₀H₃₅ClO₂Na (M + Na⁺) 365.2223, found 365.2215.

((2*S*,4*S*,5*aR*,7*aS*,11*aS*,11*bR*)-4-(((*tert*-Butyldimethylsilyl)oxy)methyl)-5*a*,8,8,11*a*-tetramethyl-3-methylenetetradecahydronaphtho[2,1-*b*]oxepin-2-ol (**28**). *tert*-Butyl hydroperoxide (0.22 mL, 1.2 mmol) was added to a solution of **24** (500 mg, 1.2 mmol) in anhydrous CH₂Cl₂ previously cooled at 0 °C, and the mixture was allowed to stir under argon atmosphere for 5 min. Then catalytic SeO₂ was added (1.3 mg, 0.12 mmol), and the mixture was allowed to stir

for 24 h. The solvent was evaporated, and ether was added (15 mL). The organic solution was washed with water (3 × 5 mL) and brine (5 mL), dried over anhydrous Na₂SO₄, and evaporated to afford a crude product that was purified by flash chromatography on silica gel (30% AcOEt/hexane) to yield **28** (400 mg, 83%). [α]_D²⁵ +58.3 (c 0.12, CHCl₃). ¹H NMR (CDCl₃, 500 MHz) δ : 0.04 (s, 6H), 0.77 (s, 3H), 0.82 (s, 3H), 0.84 (s, 3H), 0.88 (s, 9H), 1.11 (ddd, *J* = 13.4, 13.4, 4.0 Hz, 1H), 1.17 (s, 3H), 1.26–1.64 (m, 12H), 2.04 (ddd, *J* = 12.6, 12.6, 8.0 Hz, 1H), 3.52 (d, *J* = 10.5 Hz, 1H), 3.55 (s, 1H), 3.55 (d, *J* = 10.5 Hz, 1H), 4.27 (brs, 1H), 4.81 (dd, *J* = 8.0, 8.0 Hz, 1H), 4.83 (s, 1H), 5.04 (s, 1H). ¹³C NMR (CDCl₃, 125 MHz) δ : -5.2 (CH₃), -4.9 (CH₃), 16.0 (CH₃), 18.3 (C), 18.6 (CH₂), 20.3 (CH₂), 21.3 (CH₃), 23.4 (CH₃), 25.9 (3 CH₃), 33.20 (CH₂), 33.26 (C), 33.3 (CH₃), 37.5 (CH₂), 37.9 (C), 40.2 (CH₂), 41.8 (CH₂), 52.9 (CH), 56.0 (CH), 67.8 (CH₂), 69.1 (CH), 72.0 (CH), 78.0 (C), 104.3 (CH₂), 153.7 (C). IR (film): 3412, 1646, 1462, 1383, 1253, 1122, 836, 776 cm⁻¹. HRMS (FAB) *m/z*: calcd for C₂₆H₄₈O₃SiNa (M + Na⁺) 459.3270, found 459.3259.

(2*S*,4*S*,5*aR*,7*aS*,11*aS*,11*bR*)-4-(((*tert*-Butyldimethylsilyl)oxy)-methyl)-5*a*,8,8,11*a*-tetramethyl-3-methylenetetradecahydronaphtho[2,1-*b*]oxepin-2-yl Methanesulfonate (**29**). MsCl (124 mg, 1.08 mmol) and pyridine (5 mL) were added to a solution of **28** (200 mg, 0.45 mmol) in anhydrous CH₂Cl₂ (15 mL), and the mixture was allowed to stir under argon atmosphere for 12 h. Then ether was added (50 mL), and the organic solution was washed with 10% HCl (10 mL), water (2 × 10 mL), and brine (10 mL), dried over anhydrous Na₂SO₄, and evaporated to yield **29** (210 mg, 91%). [α]_D²⁵ -31.8 (c 0.1, CHCl₃). ¹H NMR (CDCl₃, 500 MHz) δ : 0.04 (s, 6H), 0.77 (s, 3H), 0.82 (s, 3H), 0.85 (s, 3H), 0.88 (s, 9H), 1.17 (s, 3H), 1.72–1.21 (m, 12H), 2.09–2.01 (m, 2H), 3.62 (d, *J* = 10.5 Hz, 1H), 3.63 (d, *J* = 10.5 Hz, 1H), 4.27 (m, 1H), 4.83 (brs, 1H), 5.05 (brs, 1H), 5.50 (t, *J* = 7.9 Hz, 1H). ¹³C NMR (CDCl₃, 125 MHz) δ : -5.1 (2 CH₃), 16.0 (CH₃), 18.4 (C), 18.6 (CH₂), 20.2 (CH₂), 21.3 (CH₃), 23.5 (CH₃), 25.8 (3 CH₃), 31.5 (CH₂), 33.2 (C), 33.3 (CH₃), 37.3 (CH₂), 37.9 (C), 40.1 (CH₂), 41.7 (CH₂), 52.5 (CH₃), 52.8 (CH), 56.0 (CH), 67.9 (CH₂), 71.2 (CH), 78.3 (C), 80.3 (C), 107.1 (CH₂), 147.8 (C). IR (film): 1727, 1631, 1462, 1385, 1359, 1253, 1177, 1122, 1082, 954, 836, 761 cm⁻¹. HRMS (FAB) *m/z*: calcd for C₂₇H₅₀O₅SSiNa (M + Na⁺) 537.3046, found 537.3061.

(4*aS*,6*aR*,7*aS*,12*aR*,12*bS*)-4,4,6*a*,12*b*-Tetramethyl-1,2,3,4,4*a*,5,6,6*a*,7*a*,8,10,12,12*a*,12*b*-tetradecahydrofuro[3,4-*b*]naphtho[1,2-*f*]oxepine (**30**). TBAF (74.6 mg, 0.28 mmol) was added to a solution of **29** (120 mg, 0.24 mmol) in anhydrous THF (10 mL), and the reflux mixture was allowed to stir for 15 h. Then the solvent was evaporated, and ether was added (25 mL). The organic solution was washed with water (3 × 10 mL) and brine (10 mL), dried over anhydrous Na₂SO₄, and evaporated to yield **30** (80 mg, 78%). [α]_D²⁵ -14.1 (c 0.14, CHCl₃). ¹H NMR (CDCl₃, 500 MHz) δ : 0.80 (s, 6H), 0.88 (s, 3H), 0.91 (dd, *J* = 12.9, 3.9 Hz, 1H), 1.15 (ddd, *J* = 14.7, 13.4, 2.7 Hz, 1H), 1.24 (s, 3H), 1.31–1.41 (m, 3H), 1.45 (dt, *J* = 13.3, 3.4 Hz, 1H), 1.56–1.79 (m, 5H), 1.90 (dd, *J* = 8.6, 2.8 Hz, 2H), 2.18–2.23 (m, 2H), 3.44 (t, *J* = 8.3 Hz, 1H), 4.06 (t, *J* = 8.1 Hz, 1H), 4.34 (dd, *J* = 12.7, 2.2 Hz, 1H), 4.40 (brd, *J* = 12.7 Hz, 1H), 4.86 (brs, 1H), 5.53 (t, *J* = 2.7 Hz, 1H). ¹³C NMR (CDCl₃, 125 MHz) δ : 16.1 (CH₃), 18.7 (CH₂), 20.6 (CH₂), 21.3 (CH₃), 23.1 (CH₃), 23.8 (CH₂), 33.3 (CH₃), 33.4 (C), 37.9 (CH₂), 38.8 (C), 39.9 (CH₂), 41.9 (CH₂), 55.8 (CH), 56.1 (CH), 69.9 (CH), 71.0 (CH₂), 72.1 (CH₂), 79.3 (C), 121.6 (CH), 141.8 (C). IR (film): 1732, 1461, 1384, 1106, 1060, 926, 755 cm⁻¹. HRMS (FAB) *m/z*: calcd for C₂₀H₃₂O₂Na (M + Na⁺) 327.2300, found 327.2286.

(4*aS*,6*aR*,7*aS*,12*aR*,12*bS*)-4,4,6*a*,12*b*-Tetramethyl-1,3,4,4*a*,5,6,6*a*,7*a*,8,12,12*a*,12*b*-dodecahydrofuro[3,4-*b*]naphtho[1,2-*f*]oxepin-10(2*H*)-one (**31**). Excess PCC was added to a solution of **30** (50 mg, 0.165 mmol) in anhydrous CH₂Cl₂ (10 mL), and the reflux mixture was allowed to stir under argon atmosphere for 12 h. When the reaction was complete, the mixture was filtered on silica gel to afford a crude product that was purified by flash chromatography on silica gel (10% ether/hexane) to yield **31** (40 mg, 84%). [α]_D²⁵ +6.4 (c 0.1, CHCl₃). ¹H NMR (CDCl₃, 500 MHz) δ : 0.80 (s, 3H), 0.83 (s, 3H), 0.89 (s, 3H), 1.14 (ddd, *J* = 13.5, 13.4, 4.1 Hz, 1H), 1.26 (s, 3H),

1.29–1.87 (m, 11H), 2.37 (m, 1H), 2.48 (dd, *J* = 19.8, 6.3 Hz, 1H), 3.86 (dd, *J* = 8.9, 7.3 Hz, 1H), 4.47 (t, *J* = 8.1 Hz, 1H), 5.15 (m, 1H), 6.96 (brd, *J* = 6.4 Hz, 1H). ¹³C NMR (CDCl₃, 125 MHz) δ : 16.0 (CH₃), 18.5 (CH₂), 20.5 (CH₂), 21.2 (CH₃), 22.7 (CH₃), 24.8 (CH₂), 33.3 (CH₃), 33.4 (C), 38.1 (CH₂), 38.9 (C), 39.8 (CH₂), 41.8 (CH₂), 55.2 (CH), 56.1 (CH), 66.7 (CH), 70.0 (CH₂), 80.3 (C), 131.8 (C), 144.1 (CH), 169.5 (C). IR (film): 1764, 1682, 1457, 1386, 1210, 1190, 1114, 1018, 772, 668 cm⁻¹. HRMS (FAB) *m/z*: calcd for C₂₀H₃₀O₃Na (M + Na⁺) 341.2093, found 341.2105.

■ ASSOCIATED CONTENT

● Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.6b01834.

¹H and ¹³C NMR spectra for all new compounds (PDF)

■ AUTHOR INFORMATION

Corresponding Authors

*E-mail: rachid@ugr.es.

*E-mail: eamr@ugr.es.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We thank the Spanish Ministry of Economy and Competitiveness (Project CTQ2014-56611-R/BQU) and the Regional Government of Andalusia (Project P11-CTS-7651) for financial support and assistance provided to the FQM-348 group. This work is related to the Ph.D. Thesis of J.A.G.

■ REFERENCES

- (1) For a review concerning the isolation and chemical and biotransformation routes of labdane-type diterpenes, including (–)-sclareol (**1**), see: Frija, L. M. T.; Frade, R. F. M.; Afonso, C. A. M. *Chem. Rev.* **2011**, *111*, 4418–4452.
- (2) Martres, P.; Perfetti, P.; Zahra, J. P.; Waegell, B. *Tetrahedron Lett.* **1993**, *34*, 3127–3128.
- (3) Barton, D. H. R.; Parekh, S. H.; Taylor, D. K.; Tse, C.-I. *Tetrahedron Lett.* **1994**, *35*, 5801–5804.
- (4) Marcos, I. S.; Laderas, M.; Diez, D.; Basabe, P.; Moro, R. F.; Garrido, N. M.; Urones, J. G. *Tetrahedron Lett.* **2003**, *44*, 5419–5422.
- (5) Decorant, R.; Vial, C.; Naef, F.; Whitesides, G. M. *Tetrahedron* **1987**, *43*, 1871–1879.
- (6) (a) Angelopoulou, D.; Demetzos, C.; Dimas, C.; Perdetzoglou, D.; Loukis, A. *Planta Med.* **2001**, *67*, 168–171. (b) Garcez, F. R.; Garcez, W. S.; da Silva, A. F. G.; de Cássia Bazzo, R.; Resende, U. M. J. *Braz. Chem. Soc.* **2004**, *15*, 767–772.
- (7) Alvarez-Manzaneda, E. J.; Chaboun, R.; Alvarez, E.; Cabrera, E.; Alvarez-Manzaneda, R.; Haidour, A.; Ramos, J. M. *Synlett* **2006**, *2006*, 1829–1834.
- (8) (a) Mihailovic, M. L. J.; Cekovic, Z.; Maksimovic, V.; Jeremic, D.; Lorenc, L. J.; Mamuzic, R. I. *Tetrahedron* **1965**, *21*, 2799–2812. (b) Mihailovic, M. L. J.; Miloradovic, M. *Tetrahedron* **1966**, *22*, 723–738. (c) Mihailovic, M. L. J.; Gojkovic, S.; Milosavljevic, S. J. J. *Serb. Chem. Soc.* **1995**, *60*, 535–541.
- (9) For reviews concerning the synthesis of seven-membered ring ethers, see: (a) Kleinke, A.; Webb, D.; Jamison, T. F. *Tetrahedron* **2012**, *68*, 6999–7018. (b) Piva, O. *Top. Heterocycl. Chem.* **2014**, *36*, 283–320.
- (10) (a) Pettit, G. R.; Herald, C. L.; Allen, M. S.; von Dreele, R. B.; Vanell, L. D.; Kao, J. P. Y.; Blake, W. J. *Am. Chem. Soc.* **1977**, *99*, 262–263. (b) Von Dreele, R. B.; Kao, J. P. Y. *Acta Crystallogr., Sect. B: Struct. Crystallogr. Cryst. Chem.* **1980**, *36*, 2695–2698. (c) Capon, R.; Ghisalberti, E. L.; Jefferies, P. R.; Skelton, B. W.; White, A. H. *Tetrahedron* **1981**, *37*, 1613–1621. For a synthesis of this compound

involving ring-closing metathesis, see: (d) Couladuros, E. A.; Vidali, V. *P. Chem. - Eur. J.* **2004**, *10*, 3822–3835.

(11) (a) Paul, V. J.; Fenical, W. *Tetrahedron Lett.* **1980**, *21*, 2787–2790. For the synthesis of this type of compounds utilizing electrophilic cyclizations mediated by ion bromonium, see: (b) Tanaka, A.; Suzuki, M.; Yamashita, K. *Agric. Biol. Chem.* **1986**, *50*, 1069–1071.

(12) Iliopoulou, D.; Mihopoulos, N.; Roussis, V.; Vagias, C. *J. Nat. Prod.* **2003**, *66*, 1225–1228.

(13) (a) Potts, B. C. M.; Capon, R. J.; Faulkner, D. J. *J. Org. Chem.* **1992**, *57*, 2965–2967. For the synthesis of this compound, see: (b) Basabe, P.; Boderó, O.; Marcos, I. S.; Díez, D.; Blanco, A.; de Román, M.; Urones, J. G. *J. Org. Chem.* **2009**, *74*, 7750–7754.

(14) Killday, K. B.; Wright, A. E.; Jackson, R. H.; Sills, M. A. *J. Nat. Prod.* **1995**, *58*, 958–960.

(15) Diols were easily prepared from the suitable natural terpenes (cupressic acid, larixol, sclareol or α -cyclocitral). Bouanou, H. Ph.D. Thesis, University of Granada, 2015.

(16) Alkoxy lead intermediates, involving tertiary hydroxyl groups, have been previously postulated in the LTA oxidation of unsaturated alcohols. See: (a) Preite, M. D.; Cuellar, M. A. *Chem. Commun.* **2004**, 1970–1971. (b) Elkhayat, Z.; Safir, I.; Dakir, M.; Arseniyadis, S. *Tetrahedron: Asymmetry* **2007**, *18*, 1589–1602. (c) Alvarez-Manzaneda, E. J.; Chahboun, R.; Alvarez, E.; Fernández, A.; Alvarez-Manzaneda, R.; Haidour, A.; Ramos, J. M.; Akhaouzan, A. *Chem. Commun.* **2012**, *48*, 606–608.

(17) Examples of reactions of Pb(IV) with both radical and cationic intermediates have been previously reported. For radical mechanisms examples, see: (a) Tsunoi, S.; Ryu, I.; Okuda, T.; Tanaka, M.; Komatsu, M.; Sonoda, N. *J. Am. Chem. Soc.* **1998**, *120*, 8692–8701. (b) Paredes, M. D.; Alonso, R. *Tetrahedron Lett.* **1999**, *40*, 3973–3976. For cationic mechanisms examples, see: (c) Cekovic, Z.; Saicic, R.; Mihailovic, M. L. *Res. Chem. Intermed.* **1989**, *11*, 257–270. (d) Abet, V.; Castillo, R. R.; Aquino, M.; Gandara, Z.; Arseniyadis, S. *Tetrahedron: Asymmetry* **2015**, *26*, 981–1035.